
- /
- Supported exchanges
- / PINK
Teva Pharmaceutical Industries Limited (TEVJF PINK) stock market data APIs
Teva Pharmaceutical Industries Limited Financial Data Overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Teva Pharmaceutical Industries Limited data using free add-ons & libraries
Get Teva Pharmaceutical Industries Limited Fundamental Data
Teva Pharmaceutical Industries Limited Fundamental data includes:
- Net Revenue: 16 772 M
- EBITDA: 4 786 M
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-29
- EPS/Forecast: NaN
Get Teva Pharmaceutical Industries Limited End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Teva Pharmaceutical Industries Limited News

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a sett...


Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations
Teva Pharmaceutical Industries (NYSE:TEVA) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4% from FY 2023). Net loss: US$1.64b (loss widened by 193% from FY 2023). US$1.45 loss...

This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point. Continue Reading View Comments

Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...
Total Revenue: $16.5 billion, up 9%. Adjusted EBITDA: $4.8 billion, up 9%. Non-GAAP EPS: $2.49, up 10%. Free Cash Flow: $2.1 billion, up 10%. Net Debt to EBITDA Ratio: Close to 3 times. AUSTEDO Revenu...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.